




Appendix A

Claim Amendments

1-10. (Canceled)

11. (Currently amended) A compound of formula I




in which

A1 and A2 are identical or different and are -O-, -C(O)-, -O-C(O)-, -NH-C(O)- or a bond,

A3 and A4 are identical or different and are 1,4-piperazinylene or a bond,

A5 and A6 are identical or different and are -C(O)-, -C(O)-NH-, -NH-C(O)- or -NH-C(O)-NH-,

M is the central building block



K1 is -B7-(C(O))_m-B9-Y1 or -B7-(C(O))_m-B9-Z1-B11-X1,


K2 is -B8-(C(O))_p-B10-Y2 or -B8-(C(O))_p-B10-Z2-B12-X2,

B1 and B2 are identical or different and are a bond or methylene,

B3, B4, B5 and B6 are identical or different and are a bond or 1-3C-alkylene,

B7, B8, B9 and B10 are identical or different and are a

bond or 1-4C-alkylene,
 B11 and B12 are identical or different and are a bond or
 methylene,
 m is 0,
 p is 0,
 X1 and X2 are identical or different and are selected from
 the groups below



Y1 and Y2 are imidizol-1-yl,
 Z1 and Z2 are identical or different and are 5,2-
 pyridinylene, 6-methyl-5,2-pyridinylene, 4,1-
 piperidinylene, 3,6-indazolylene, 3,6-indolylene, 1,3-
 phenylene, 1,4-phenylene, 1,3-cyclohexylene or 1,4-
 cyclohexylene,
 and where on the direct route along the bonds between the
 terminal nitrogen atom as defined in K1 on the one hand and
 the terminal nitrogen atom as defined in K2 on the other
 hand, 20 to 40 bonds have to be present, wherein each
 double bond is counted as one bond and each triple bond is
 counted as one bond, or a solvate, hydrate, salt, hydrate
 of a salt or solvate of a salt thereof, or an N-oxide of
 the nitrogen-containing heteroaryls, heterocycloalkyls,
 heteroarylenes and heterocycloalkylenes, or a solvate,

hydrate, salt[[,]] or hydrate of a salt, ~~or solvate of a salt~~ thereof,

wherein the compounds in which one or more of the variables B1, B2, B3, B4, B5, B6, B7, B8, B9, B10, B11 or B12 may assume the meaning of a bond resulting in the direct linkage of two heteroatoms or carbonyl groups are excluded.

12. (Currently amended) A compound of formula I according to claim 11, in which



A1 and A2 are -O-C(O)-,


A3 and A4 are 1,4-piperazinylene,

A5 and A6 are identical or different and are -C(O)- or

-C(O)-NH-,

M is a central building block selected from the groups below





K1 is -B7-(C(O))_m-B9-Z1-B11-X1,

K2 is -B8-(C(O))_p-B10-Z2-B12-X2,

B1, B2, B3, B4, B5 and B6 are a bond,

B7 and B8 are identical or different and are a bond or methylene,

B9 and B10 are a bond,

B11 and B12 are methylene,

m is 0,

p is 0,

X1 and X2 are amino,

Z1 and Z2 are identical or different and are 1,4-phenylene or 1,4-cyclohexylene,

or a ~~solvate~~, hydrate, salt[[,]] or hydrate of a salt,~~or solvate of a salt~~ thereof.

13. (Currently amended) A compound of formula I according to claim 11 with the chemical name

1,2-bis[4-trans-4-aminomethylcyclohexylcarbonyl)-1-piperazinylcarbonyl-1-oxyprop-2ynyl]benzene;

1,4-bis[4-trans-4-aminomethylcyclohexylcarbonyl)-1-piperazinylcarbonyl-1-oxyprop-2ynyl]benzene;

1,2-bis[4-(4-aminomethylbenzylaminocarbonyl)-1-piperazinylcarbonyl-1-oxyprop-2ynyl]benzene;

1,3-bis[4-(4-aminomethylbenzylaminocarbonyl)-1-piperazinylcarbonyl-1-oxyprop-2ynyl]benzene;
or a ~~solvate~~, hydrate, salt[[,]] or hydrate of a salt,~~or~~
~~solvate of a salt~~ thereof.


14. (Currently amended) A pharmaceutical composition comprising a compound of claim 11 or a pharmaceutically acceptable ~~solvate~~, hydrate, salt[[,]] or hydrate of a salt,~~or solvate of a salt~~ thereof, or an N-oxide of a compound of claim 11 or a pharmaceutically acceptable ~~solvate~~, hydrate, salt[[,]] or hydrate of a salt ~~or solvate of a salt~~ thereof; and a suitable pharmaceutical excipient.

15. (Currently amended) A method of treating a disease or disorder in a patient comprising administering to a patient in need thereof a therapeutically effective amount of a compound of claim 11 or a pharmaceutically acceptable ~~solvate~~, hydrate, salt[[,]] or hydrate of a salt ~~or solvate of a salt~~ thereof, or an N-oxide of a compound of claim 11 or a pharmaceutically acceptable ~~solvate~~, hydrate, salt[[,]] or hydrate of a salt ~~or solvate of a salt~~ thereof,

wherein the disease or disorder is selected from the group consisting of ~~bronchitis, allergic bronchitis, asthma, bronchial asthma, COPD, allergic conjunctivitis, allergic rhinitis, arthritis, rheumatoid arthritis, periodontitis, anaphylaxis, interstitial cystitis, dermatitis, psoriasis, sclerodermatitis, Crohn's disease~~ and inflammatory bowel disease.







16. (Currently amended) The method of claim 15, wherein the disease or disorder is ~~selected from the group consisting of bronchitis, allergic bronchitis, asthma, bronchial asthma, and COPD.~~









17. (Currently amended) A compound of formula I




in which

-B1-A1-B3-A3-B5-A5- and -B2-A2-B4-A4-B6-A6- are identical or different and are selected from the groups below





M is the central building block



K1 is $-B7-(C(O))_m-B9-Y1$ or $-B7-(C(O))_m-B9-Z1-B11-X1$,


K2 is $-B8-(C(O))_p-B10-Y2$ or $-B8-(C(O))_p-B10-Z2-B12-X2$,

B7, B8, B9, B10, B11 and B12 are identical or different and
are a bond or 1-2C-alkylene,

m is 0,

p is 0,

X1 and X2 are identical or different and are selected from
the groups below



Y1 and Y2 are imidizol-1-yl,


Z1 and Z2 are identical or different and are 5,2-

pyridinylene, 6-methyl-5,2-pyridinylene, 4,1-piperidinylene, 3,6-indazolylene, 3,6-indolylene, 1,3-phenylene, 1,4-phenylene, 1,3-cyclohexylene or 1,4-cyclohexylene,


and where on the direct route along the bonds between the terminal nitrogen atom as defined in K1 on the one hand and the terminal nitrogen atom as defined in K2 on the other hand, 20 to 40 bonds have to be present, wherein each double bond is counted as one bond and each triple bond is counted as one bond, or a ~~solvate~~, hydrate, salt[[,]] or hydrate of a salt ~~or solvate of a salt~~ thereof, or an N-oxide of the nitrogen-containing heteroaryls, heterocycloalkyls, heteroarylenes and heterocycloalkylenes, or a ~~solvate~~, hydrate, salt[[,]] or hydrate of a salt ~~or solvate of a salt~~ thereof.

18. (Currently amended) A compound of formula I according to claim 17 in which

-B1-A1-B3-A3-B5-A5- and -B2-A2-B4-A4-B6-A6- are identical or different and are selected from



M is the central building block



K1 is -B7-(C(O))_m-B9-Z1-B11-X1,

K2 is -B8-(C(O))_p-B10-Z2-B12-X2,

B7 and B8 are identical or different and are a bond or methylene,

B9 and B10 are a bond,

B11 and B12 are methylene,

m is 0,

p is 0,

X1 and X2 are amino,

Z1 and Z2 are identical or different and are 1,4-phenylene or 1,3-phenylene,

or a ~~solvate~~, hydrate, salt[[,]] or hydrate of a salt ~~or solvate of a salt~~ thereof.

19. (Currently amended) A compound of formula I according to claim 17 with the chemical name

1,3-Bis-(4-aminomethylbenzylaminocarbonyl-1-oxyprop-2-ynyl)-benzene;

1,2-Bis-(4-aminomethylbenzylaminocarbonyl-1-oxyprop-2-ynyl)-benzene;

1,4-Bis-(4-aminomethylbenzylaminocarbonylmethyl-1-oxyprop-2-ynyl)-benzene;

1,3-Bis-(4-aminomethylbenzylaminocarbonylmethyl-1-oxyprop-2-ynyl)-benzene;

1,4-Bis-(4-aminomethylbenzylcarbonyl-1-aminoprop-2-ynyl)-benzene;

1,2-Bis-(4-aminomethylbenzylcarbonyl-1-aminoprop-2-ynyl)-benzene;

1,4-Bis-(4-aminomethylphenylethylcarbonyl-1-aminoprop-2-ynyl)-benzene;

or a ~~solvate~~, hydrate, salt[[,]] or hydrate of a salt ~~or solvate of a salt~~ thereof.

20. (Currently amended) A pharmaceutical composition comprising a compound of claim 17 or a pharmaceutically acceptable ~~solvate~~, hydrate, salt[[,]] or hydrate of a salt ~~or solvate of a salt~~ thereof, or an N-oxide of a compound of claim 17 or a pharmaceutically acceptable ~~solvate~~, hydrate, salt[[,]] or hydrate of a salt ~~or solvate of a salt~~ thereof; and a suitable pharmaceutical excipient.

21. (Currently amended) A method of treating a disease or disorder in a patient comprising administering to a patient in need thereof a therapeutically effective amount of a compound of claim 17 or a pharmaceutically acceptable ~~solvate~~, hydrate, salt[[,]] or hydrate of a salt ~~or solvate of a salt~~ thereof,

or an N-oxide of a compound of claim 17 or a pharmaceutically acceptable ~~solvate~~, hydrate, salt[[,]] or hydrate of a salt ~~or solvate of a salt~~ thereof,

wherein the disease or disorder is selected from the group consisting of ~~bronchitis, allergic bronchitis, asthma, bronchial asthma, COPD,~~ allergic conjunctivitis, allergic

rhinitis, ~~arthritis, rheumatoid arthritis, periodontitis,~~
~~anaphylaxis, interstitial cystitis, dermatitis,~~ psoriasis,
~~sclerodermatitis, Crohn's disease~~ and inflammatory bowel
disease.

22. (Currently amended) The method of claim 21, wherein the
disease or disorder is ~~selected from the group consisting~~
~~of bronchitis, allergic bronchitis, asthma, bronchial~~
~~asthma, and COPD.~~